(Q33347889)

English

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

lung small cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

James R Jett

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Alan K Hatfield

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shauna Hillman

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael D Bauman

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

James A Mailliard

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

John W Kugler

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Roscoe F Morton

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Randolph S Marks

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ralph Levitt

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 May 2003

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

97

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2498-2503

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurable or assessable disease in lung cancer trials: does it matter?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11377

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11377

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33347889&oldid=1584465689"